Hikma Gears Up To Enter US Biosimilars Market With Ustekinumab Nod
Bio-Thera-Partnered Starjemza Becomes Eighth Stelara Rival To Be Approved By FDA
Hikma is set to make its first launch into the competitive US biosimilars market after its Bio-Thera-partnered Stelara rival, Starjemza, was approved by the FDA.
